PCDHGC3 Promoter Methylation Distinguishes Adrenocortical Carcinoma From Benign Tumors
PCDHGC3 promoter hypermethylation distinguishes adrenocortical carcinoma from benign adenomas and predicts shorter event-free survival in patients with localized disease.

